Publications by authors named "T Winder"
Article Synopsis
- This study evaluates the use of durvalumab combined with platinum and gemcitabine for treating biliary tract cancers, aiming to validate previous trial results in a real-world setting and investigate how molecular profiles may affect patient outcomes.* -
- The analysis involved 102 patients from multiple cancer centers, revealing a 71.57% disease control rate and a median overall survival of 13.61 months, with younger patients showing better outcomes.* -
- Findings indicate that while no specific molecular profiles predicted better responses to durvalumab, patients receiving tailored second-line therapy showed a potential survival advantage, highlighting the need for further research in this area.*
Background: Patients with bone metastases from solid tumors often have additional treatment with bone targeted agents (BTAs) to avoid symptomatic skeletal events (SSEs) such as clinically significant pathological fracture leading toradiation therapy or surgery to the bone, spinal cord compression, or hypercalcemia. The absolute value of BTA treatment in the era of immunotherapy (IO) is unknown.
Methods: Patients with bone metastases treated with immunotherapy within the Alpine Tumor Immunology Registry were compared based on whether they received an additional BTA such as denosumab or zoledronic acid.
Monoclonal antibodies, as tixagevimab/cilgavimab, have been introduced as prophylaxis against COVID-19 infections in high-risk populations. However, data on efficacy are limited. This study investigates efficacy and tolerability of tixagevimab/cilgavimab in hematological patients under real-life conditions.
View Article and Find Full Text PDFImportance: Atrial cardiopathy is associated with stroke in the absence of clinically apparent atrial fibrillation. It is unknown whether anticoagulation, which has proven benefit in atrial fibrillation, prevents stroke in patients with atrial cardiopathy and no atrial fibrillation.
Objective: To compare anticoagulation vs antiplatelet therapy for secondary stroke prevention in patients with cryptogenic stroke and evidence of atrial cardiopathy.